Abby Reinhard, Assistant Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2021. Email her at firstname.lastname@example.org
Research Needs Identified for Transgender, Gender-Diverse Patients With Headache
A narrative review was conducted to evaluate the relationship between gender-affirming hormone therapy and headache to advance care and improve resources for the transgender and gender-diverse population.
No Occurrence of Symptomatic ICH With LT3001 in Acute Ischemic Stroke
Lumosa Therapeutics announced that phase 2b of LT3001 met its primary safety end point, with data indicating its potential for clinical benefit.
PDE10A Inhibitor Being Evaluated in Tourette Syndrome Phase 2a Study
The investigational agent NOE-105 has previously been found safe for treating adults with Tourette syndrome at 30-mg daily doses.
Dosing of WVE-004 Treatment Begins In Frontotemporal Dementia and ALS
Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.
Investigating the Future of Wearable Sensors for Automatic Seizure Detection
Jianbin Tang, data scientist and research leader from IBM Research Australia, and colleagues spoke on findings from their recent study and plans for a newly developed artificial intelligence-based model.
Pimavanserin Associated With Lower Relapse Risk of DRP, Symptom Reduction
The phase 3 trial of pimavanserin in dementia-related psychosis, HARMONY, was previous halted due to positive efficacy signs at interim analysis. The drug is currently indicated for use in treating Parkinson disease-related psychosis.
Wearable Sensors Feasible for Automatic Seizure Detection
Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.
Interim Data on DNL310 Show Improvement in MPS II Symptoms
Results and safety data from the phase 1/2 study of the therapy for Hunter syndrome/MPS II were presented at MPS 2021, the 18th International Symposium on MPS and Released Diseases, on July 25.
Significant Association Found Between Age of Diabetes Onset and Subsequent Dementia
Investigators analyzed electronic health records from 10,095 participants over a median follow-up period of 31.7 years.
6-Week Dosing of Natalizumab Effective, May Reduce PML Risk
Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates a significant reduction in the probability of progressive multifocal leukoencephalopathy infection.
Novel PET Imaging Tracer Shows Promise for Parkinson Disease Diagnosis
AC Immune, the company presenting the data at the 2021 AAIC meeting, also recently acquired an a-syn vaccine, Affiris PD01.
Anti-Amyloid Beta Vaccine Safe and Well-Tolerated in Adults With Down Syndrome
Phase 1b study results were presented at AAIC 2021, supporting the need for accelerated clinical development of ACI-24 in Alzheimer disease related to DS.
Baseline Characteristics Announced for Lecanemab Phase 3 Study
Participants will be enrolled for 18 months, with baseline data provided and compared to the lecanemab phase 2 study cohort.
Pharmacokinetics of Novel Migraine Preventives Evaluated for Drug-Drug Interactions
Investigators found occurrence of DDIs through alterations in cytochrome P450 isoenzyme activity, which can be complicated by genetic polymorphism for metabolic enzymes.
Sleep Classification Prevalence in OSA Differs From Whites for Hispanics/Latinos
Findings were consistent with recent reports from the Sleep Apnea Global Interdisciplinary Consortium; however, significant differences were identified in comparison to White participants.
Gamma Sensory Stimulation Safe for Mild-to-Moderate AD
Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.
Prevalence of MS and NMOSD in Indigenous Populations Dependent on Ancestry
Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.
AI-Computerized Cognitive Assessment Aids in Diagnosing MCI and Mild AD
The Integrated Cognitive Assessment showed convergent validity with both MoCA and ACE and offers potential for remote measurement of cognitive performance in Alzheimer disease and mild cognitive impairment.
Patients With MS on Rituximab at Higher Risk for COVID-19 Hospitalization
While rituximab treatment puts patients at a higher risk for infectious disease in general, use of such treatment poses particular risk for severe COVID-19 infections in patients with MS.
Association Identified Between DMT Strategy and Depression in MS
Data suggest a link between different disease-modifying strategies and the occurrence of depression when treating patients with MS.
TRAIN-AD Intervention Strategies Fail to Reduce Antimicrobial Use in AD Patients
The study data suggest that intervention strategies to improve antimicrobial and burdensome intervention for suspected LRIs and UTIs are ineffective.
Racial and Ethnic Disparities Identified in AD Clinical Trial Enrollment
Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.
EFRONT Study Announced to Assess Genetic Mutations in FTD
The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.
New tES System Gets Breakthrough Designation in Refractory Focal Epilepsy
The FDA breakthrough device designation follows a pilot study where patients showed a 44% median reduction in seizures when treated with Neuroelectrics’ transcranial electrical stimulation platform.
Viltolarsen Demonstrates Long-Term Benefits in Treating DMD
Efficacy results from a 109-week interim analysis showed improvement for patients treated with viltolarsen when compared to the matched DMD historical control group.
Silent MI Identified as Associated Risk Factor for Ischemic Stroke
Research into silent myocardial infarction may help identify cause of ischemic strokes that lack etiology, as well as identify better therapeutic strategies to combat recurring stroke.
nVNS Improves Cognitive Performance Under Sleep Deprivation Stress
The study was conducted at Wright-Patterson Air Force Base to examine the effect of fatigue on cognition and mood within the military population.
Amantadine Improves Motor Function, Dyskinesia in Parkinson Disease
Analyses suggest treatment of Parkinson disease with amantadine (Gocovri; Adamas) may improve freezing and tremor, as well as other M-EDLs.
Quell TENS Device to be Used in NMOSD Study
NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.
NIH Awards Funding to Study RNS System in Lennox-Gastaut Syndrome
The grant will fund a new study to evaluate the effectiveness of brain-responsive neuromodulation in patients with LGS. The study is expected to begin accepting patients in the second half of 2022.
2 Commerce Drive Cranbury, NJ 08512